Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world evidence study of COPAXONE (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding

Next Previous
X
Search
Trial Profile

A real world evidence study of COPAXONE (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms COBRA

    • Most Recent Events

    • 10 Feb 2022 According to a Teva Pharmaceuticals Europe media release, COPAXONE 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated. The product is now approved by EU health authorities for use in breastfeeding. The label update follows the review of clinical and non-clinical evidence, including latest data from the COBRA real world evidence study.
    • 15 Oct 2021 Results of subgroup analysis assessing offspring outcomes among breastfeeding mothers on glatiramer acetate treatment for relapsing multiple sclerosis, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 13 Oct 2021 Acording to a Teva Pharmaceuticals Europe media release, subgroup analyses results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top